Survey
Quarterly Survey: Geographic Atrophy (GA) Treatments including Apellis' Syfovre and Iveric Bio's Izervay January 2024
Ticker(s): APLS, ISEE20 Retina Specialists completed the survey
How many patients with Geographic Atrophy (GA) does your practice manage?
How would you best describe your practice?
- Academic
- Community
- Private
How many patients with Geographic Atrophy (GA) are in your practice?
- Foveal (# of pts)
- Extrafoveal (# of pts)
How many GA patients did you administer the following injection treatments in the last 30 days?
- Syfovre
- Izervay
How many of your GA patients do you expect to administer the following injections in the next 30 days?
How many of your GA patients stopped receiving each of the following in the past 30 days?
How would you rate Syfovre on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
How would you rate Izervay on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
Apellis updated the Syfovre label to include the safety events of vasculitis. Does the label update resolve your concerns, if any? Please elaborate.
How does the updated label to include the safety events of vasculitis impact how you use Syfovre, and do you think the risk acceptable?
How do you expect usage of Syfovre in your practice change moving forward?
What are the key distinctions between Syfovre and Izervay in terms of their effects or outcomes?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Syfovre in treating GA?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Izervay in treating GA?
Are you familiar with the cases of occlusive retinal vasculitis reported by the ASRS ReST committee on Saturday July 15th, 2023?
Are you familiar with Iveric Bio’s Izervay and the data to date?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
